Dr Reddy’s Enters OTC Eyecare Space

Dr Reddy’s has announced the launch of its OTC versions of Pataday olopatadine solution in the US. The firm’s entry into the OTC eyecare space follows other OTC launches of rivals to Voltaren and Nicorette earlier this year.

OTC

Dr. Reddy's Laboratories Ltd. enters the OTC vision care with the US launch of olopatadine hydrochloride 0.2% and 0.1% ophthalmic solutions, generic equivalents of two Pataday brand eye allergy formulations approved in an OTC switch earlier this year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business